The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma
Business Of Biotech
00:00
Are You Sticking With the CDMO?
Audrey Greenberg Sumit Fermah: You have to balance speed with quality that's for certain as we said earlier these are curative treatments and everyone's chasing the patient but you cannot sacrifice quality. It's a marathon not just print, and we all have to be focused on the patient and balance that with the FDA along with our capital requirements. Matt pillar: I'm excited to see what the future holds and we'll all be part of that story. And if you'd like what you heard today, hit that subscribe button. Give us five stars.
Transcript
Play full episode
